{"url_path":"/sec/slxnw/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 Exhibits and Financial Statement Schedules","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002805-index.html","accession_number":"0001178913-26-002805","cik":"0002022416","ticker":"SLXN","issuer_name":"Silexion Therapeutics Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/2022416/0001178913-26-002805-index.html","primary_entity_key":"0002022416","primary_entity_name":"Silexion Therapeutics Corp"},"word_count":1674,"has_tables":true,"body_markdown":"Item 15. Exhibits and Financial Statement Schedules\n\n \n\n(a)\n\nThe following documents were filed as part of the Original 10-K:\n\n \n\n(1)\n\nOur financial statements as of, and for the year ended December 31, 2025, which were included in the “F-“ pages of the Original 10-K.\n\n \n\n(3)\n\nThe exhibits are listed in the following Exhibit Index:\n\n \n\nExhibit No.\n\n \n\nDescription\n\n[3.1](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm)\n\n \n\n[Amended and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm)\n\n[3.2](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm)\n\n \n\n[Ordinary Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on November 29, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm)\n\n[3.3](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_3-1.htm)\n\n \n\n[Ordinary Resolution Effecting 1‑for‑15 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on July 29, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_3-1.htm)\n\n[3.4](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002985/exhibit_3-1.htm)\n\n \n\n[Ordinary Resolution Approving Increase in Authorized Share Capital to $121,500 (9,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on August 19, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002985/exhibit_3-1.htm)\n\n[3.5](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/exhibit_3-1.htm)\n\n \n\n[Ordinary Resolution Approving Increase in Authorized Share Capital to $796,500 (59,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on May 5, 2026)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/exhibit_3-1.htm)\n\n[4.1*](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_4-1.htm)\n\n \n\n[Description of Securities of Silexion Therapeutics Corp registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_4-1.htm)\n\n[4.2](https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm)\n\n \n\n[Warrant Agreement, dated February 19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to Moringa Acquisition Corp’s Current Report on Form 8-K, filed with the SEC on February 22, 2021)](https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm)\n\n[4.3](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm)\n\n \n\n[Assignment, Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm)\n\n[4.4](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_4-1.htm)\n\n \n\n[Warrant Adjustment Notice, dated November 29, 2024, in respect of 1-for-9 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on November 29, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_4-1.htm)\n\n[4.5](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_4-1.htm)\n\n \n\n[Warrant Adjustment Notice, dated July 29, 2025, in respect of 1‑for‑15 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on July 29, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_4-1.htm)\n\n[10.1](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm)\n\n \n\n[Amended and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.’s pre-Business Combination shareholders and Greenstar, L.P. (incorporated by reference to Exhibit 10.4 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm)\n\n[10.2](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm)\n\n \n\n[Amended and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa Sponsor, L.P. (incorporated by reference to Exhibit 10.5 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm)\n\n[10.3](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm)\n\n \n\n[Form of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and each of its executive officers and directors (incorporated by reference to Exhibit 10.6 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm)\n\n[10.4.1#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm)\n\n \n\n[Employment Agreement, dated April 1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1 to Amendment No. 3 to the Company’s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm).\n\n[10.4.2#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm)\n\n \n\n[Amendment No. 1 to Employment Agreement, dated May 2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.2 to Amendment No. 3 to the Company’s Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm)\n\n \n\n \n\n \n\n[10.5.1#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm)\n\n \n\n[Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm)\n\n[10.5.2#](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002037/zk2635046.htm)\n\n \n\n[Amendment to Section 5(b)(i) of the Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Annex C to Silexion Therapeutics Corp’s Proxy Statement on Schedule 14A, filed with the SEC on April 9, 2026)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002037/zk2635046.htm)\n\n[10.6#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm)\n\n \n\n[Silexion Therapeutics Ltd. 2013 Share Option Plan (incorporated by reference to Exhibit 10.14 to Silexion Therapeutics Corp’s Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm)\n\n[10.7](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-1.htm)\n\n \n\n[Form of Ordinary Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-1.htm)\n\n[10.8](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-3.htm)\n\n \n\n[Form of Placement Agent Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 17, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-3.htm)\n\n[10.9](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-2.htm)\n\n \n\n[Form of Ordinary Share Purchase Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-2.htm)\n\n[10.10](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-3.htm)\n\n \n\n[Form of Placement Agent Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-3.htm)\n\n[10.11](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-2.htm)\n\n \n\n[Form of Ordinary Share Purchase Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 1, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-2.htm)\n\n[10.12](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-3.htm)\n\n \n\n[Form of Placement Agent Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp’s Current Report on Form 8-K filed with the SEC on August 1, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-3.htm)\n\n[10.13](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-1.htm)\n\n \n\n[Form of Series A Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-1.htm)\n\n[10.14](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-2.htm)\n\n \n\n[Form of Series B Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.2 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-2.htm)\n\n[10.15](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-4.htm)\n\n \n\n[Form of Placement Agent Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.4 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 12, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-4.htm)\n\n[10.16](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/exhibit_10-1.htm)\n\n \n\n[At‑The‑Market Offering Agreement, dated September 26, 2025, by and between Silexion Therapeutics Corp and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp’s Current Report on Form 8‑K filed with the SEC on September 26, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/exhibit_10-1.htm)\n\n[19.1](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_19-1.htm)\n\n \n\n[Insider Trading Policy of Silexion Therapeutics Corp (incorporated by reference to Exhibit 19.1 to Silexion Therapeutics Corp’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_19-1.htm)\n\n[21.1*](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_21-1.htm)\n\n \n\n[List of Subsidiaries](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_21-1.htm)\n\n[23.1*](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_23-1.htm)\n\n \n\n[Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm of Silexion Therapeutics Corp](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_23-1.htm)\n\n[31.1*](exhibit_31-1.htm)[*](exhibit_31-1.htm)\n\n \n\n[Certification of Silexion Therapeutics Corp’s Chief Executive Officer (Principal Executive Officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit_31-1.htm)\n\n[31.2*](exhibit_31-2.htm)[*](exhibit_31-2.htm)\n\n \n\n[Certification of Silexion Therapeutics Corp’s Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit_31-2.htm)\n\n[32.1*](exhibit_32-1.htm)[**](exhibit_32-1.htm)\n\n \n\n[Certification of Silexion Therapeutics Corp’s Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit_32-1.htm)\n\n[97.1](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_97-1.htm)\n\n \n\n[Silexion Therapeutics Corp Policy for Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to Silexion Therapeutics Corp’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_97-1.htm)\n\n \n\n101.INS*Inline XBRL Instance Document.\n\n101.SCH*Inline XBRL Taxonomy Extension Schema Document.\n\n101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.\n\n101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.\n\n101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.\n\n101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.\n\n104* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n*     Filed with the Original 10-K.\n\n**   Filed with this Amendment. \n\n*** Furnished with this Amendment.\n\n# Indicates management contract or compensatory plan, contract or arrangement.\n\n \n\nSIGNATURES\n\n \n\n            Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\nSilexion Therapeutics Corp\n\n \n\n \n\nBy:\n\n/s/ Ilan Hadar\n\nName:\n\nIlan Hadar\n\nTitle:\n\nChairman of the Board and Chief Executive Officer\n\nDate:\n\nMay 19, 2026\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.\n\n \n\nName\n\n \n\nPosition\n\n \n\nDate\n\n \n\n \n\n \n\n \n\n \n\n/s/ Ilan Hadar\n\n \n\nChairman of the Board and Chief Executive Officer\n\n \n\nMay 19, 2026\n\nIlan Hadar\n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Mirit Horenshtein Hadar\n\n \n\nChief Financial Officer\n\n \n\nMay 19, 2026\n\nMirit Horenshtein Hadar\n\n \n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Ruth Alon\n\n \n\nDirector\n\n \n\nMay 19, 2026\n\nRuth Alon\n \n \n \n \n\n \n\n/s/ Dror Abramov\n \n\nDirector\n\n \n\nMay 19, 2026\n\nDror Abramov\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Avner Lushi\n\n \n\nDirector\n\n \n\nMay 19, 2026\n\nAvner Lushi\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Shlomo Noy\n\n \n\nDirector\n\n \n\nMay 19, 2026\n\nShlomo Noy\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n/s/ Amnon Peled\n\n \n\nDirector\n\n \n\nMay 19, 2026\n\nAmnon Peled"}